Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized amoxicillin-clavulanic acid for acute exacerbations of COPD
NL-OMON21366Phase 2Not yet recruiting
- Sponsor
- Medisch Spectrum Twente
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amoxicillin + clavulanate in chronic obstructive pulmonary disease (COPD), sponsored by Medisch Spectrum Twente. Primary endpoint: Safety and tolerability of nebulized amoxicillin-clavulanic acid. Planned start May 2013; status: not yet recruiting.
02
Drugs
amoxicillin + clavulanate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON21366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21366.